



In Re the Application of:  
THOMAS, David, et al.

Serial No.: 09/810,883

Filed: March 16, 2001

For: BISPECIFIC MOLECULES CROSS-LINKING ITIM AND ITAM FOR THERAPY

Group Art Unit: 1614

**Examiner: To Be Assigned**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**Dear Sir:**

**RESPONSE TO NOTICE TO FILE MISSING PARTS and  
PRELIMINARY AMENDMENT**

Applicants hereby submit the executed declaration for this application along with the required declaration surcharge of \$65.00.

An additional claims fee of \$107.00 (2 independent claims (\$80.00) and 3 dependent claims (\$27.00)) is also attached. If any additional fees are due, please charge the deposit account # 20-0087.

**Before examination of this application, please enter the following amendments:**

### IN THE SPECIFICATION:

Please insert the following sentence as the first line of the specification:

--This application is a continuation-in-part of U.S. Application No. 09/440,310, filed November 17, 1999, and claims priority under 35 U.S.C. §119e to U.S. Provisional Application No. 60/108,816 filed on November 17, 1998.--

**IN THE CLAIMS:**

Please add the following new claims:

24. A bispecific antibody that targets an ITAM and an ITIM receptor on mast cells or basophils which inhibits the release of TNF- $\alpha$  from mast cells or basophils.
25. The bispecific antibody of claim 24, wherein the ITAM is Fc $\epsilon$ RI and the ITIM is Fc $\epsilon$ RII.
26. The bispecific antibody of claim 24, wherein the inhibition of histamine release is most effective at an antibody concentration ranging from 0.1 to 1  $\mu$ g/ml.
27. A method of inhibiting the release of TNF- $\alpha$  from mast cells comprising administering to a patient in need of such treatment an effective amount of a bispecific antibody that targets an ITAM and an ITIM receptor on mast cells or basophils.
28. The method of claim 27, wherein the bispecific antibody targets the ITAM Fc $\epsilon$ RI and the ITIM Fc $\epsilon$ RII.--


09810883-061501

**REMARKS**

Claims 1-28 are now pending in this application. Applicants have added new claims 24-28. Support for these claims can be found in the specification as a whole, for example in figure 10, pages 4-5, and page 23. No new matter has been introduced by these amendments.

Respectfully Submitted,

Dated: June 15, 2001.

BY:   
Cheryl A. Liljestrand  
Reg. No. 45,275

09/810,883-01501  
TNX 98-08-01